10-Q: Xeris Biopharma Reports Strong Revenue Growth, Faces Debt Extinguishment Loss

Xeris Biopharma Holdings, Inc. announced a 33.1% increase in total revenue for the six months ended June 30, 2026, driven by significant growth in Recorlev, though a substantial loss on debt extinguishment impacted net results.

Summary

• Total revenue for the six months ended June 30, 2026, increased by 33.1% to $175.2 million, compared to $131.7 million in the prior year period.
• Product revenue, net, grew by 38.2% to $173.5 million, primarily fueled by an 87.0% increase in Recorlev net revenue.
• A significant loss on debt extinguishment of $30.8 million was recognized in the second quarter of 2026.
• The company reported a net loss of $28.9 million for the six months ended June 30, 2026, an increase from $11.1 million in the same period of 2025.
• Cash provided by operating activities was $18.1 million for the six months ended June 30, 2026, a significant improvement from $9.8 million used in the prior year period.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with strong revenue growth in Recorlev offset by a significant loss on debt extinguishment and continued net losses.

Positives

• Recorlev net revenue saw substantial growth, increasing by 87.0% to $106.5 million for the six months ended June 30, 2026.
• Total revenue increased by 33.1% to $175.2 million for the six months ended June 30, 2026.
• Operating income improved significantly to $13.1 million for the six months ended June 30, 2026, from $1.4 million in the prior year period.
• Net cash provided by operating activities was $18.1 million for the six months ended June 30, 2026, a positive shift from a net cash used of $9.8 million in the prior year period.
• The company has $121.7 million in cash and cash equivalents as of June 30, 2026, indicating sufficient liquidity for the next twelve months.

Negatives

• A substantial loss on debt extinguishment of $30.8 million was recorded in the second quarter of 2026.
• Net loss for the six months ended June 30, 2026, was $28.9 million, an increase from $11.1 million in the prior year period.
• Gvoke net revenue decreased by 2.2% to $43.3 million for the six months ended June 30, 2026.
• Royalty, contract and other revenue decreased by 71.2% to $1.8 million for the six months ended June 30, 2026, primarily due to a milestone recognition in the prior year.
• Selling, general and administrative expenses increased by 29.1% to $114.2 million for the six months ended June 30, 2026, driven by increased personnel costs.

Risks

• The company is involved in patent infringement lawsuits concerning Recorlev, with a bench trial tentatively scheduled for November 2028.
• The filing of Abbreviated New Drug Applications (ANDAs) for generic versions of Recorlev triggered an automatic stay of FDA approval until up to June 30, 2029.
• The company may receive additional Notice Letters from ANDA filers seeking approval of a generic version of Recorlev and may file additional lawsuits.
• The company has an accumulated deficit of $700.2 million as of June 30, 2026.
• There is no assurance that future financing will be available on acceptable terms, or at all, to meet capital requirements.

Future Outlook

The company believes its current cash resources are sufficient for at least the next twelve months. However, it may incur substantial expenditures to support commercialization and R&D, and may need to seek additional debt and/or equity financing. Profitability is not assured even with successful commercialization.

Management Comments

• Stock-based compensation expense related to RSUs is recognized on a straight-line basis over the grantee's requisite service period.
• The Company's strategy is to continue building a profitable biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases.
• We believe this will generate value to all of our stakeholders.

Industry Context

StockSavvy.ai notes that Xeris Biopharma operates in the competitive biopharmaceutical sector, focusing on niche therapeutic areas. The strong growth in Recorlev is a positive indicator, but the significant loss on debt extinguishment and ongoing net losses highlight the capital-intensive nature and inherent risks of drug development and commercialization.

Comparison to Industry Standards

• The revenue growth for Recorlev (87.0% for six months) significantly outpaces the typical growth rates seen in established biopharmaceutical products, suggesting strong market penetration or unmet need.
• The net loss of $28.9 million for six months is substantial, but not uncommon for commercial-stage biopharma companies investing heavily in sales, marketing, and pipeline development.
• The company's strategy of leveraging proprietary formulation technologies (XeriSol and XeriJect) aligns with industry trends of seeking differentiated drug delivery systems to improve patient compliance and therapeutic outcomes.
• The significant increase in SG&A expenses (29.1%) is consistent with companies scaling their commercial operations, particularly for a product like Recorlev which is experiencing rapid growth.

Legal Proceedings

• Patent infringement lawsuits filed against Torrent Pharmaceuticals, Somerset Therapeutics, Sandoz, Zydus Lifesciences, and Novitium Pharma regarding generic versions of Recorlev.
• These lawsuits allege infringement of four Orange Book-listed patents covering Recorlev, set to expire in March 2040.
• The lawsuits triggered an automatic stay of FDA approval of ANDAs until up to June 30, 2029.
• A bench trial is tentatively scheduled for November 2028.
• Management is not aware of any other pending or threatened legal actions that would have a material impact on the financial position or results of operations.

Stakeholder Impact

• Shareholders may be impacted by the increased net loss and the potential need for future capital raises, which could dilute existing ownership.
• The ongoing patent litigation for Recorlev could impact future revenue streams if generic competition is allowed sooner than anticipated.
• Employees may be affected by the increased SG&A expenses, which include higher personnel costs to support commercial expansion.
• Customers (patients and healthcare providers) will continue to have access to therapies for chronic endocrine and neurological diseases.

Next Steps

• Continue selling and marketing efforts related to commercial products (Recorlev, Gvoke, Keveyis).
• Continue research and development efforts, including advancing the Phase 3 clinical trial for XP-8121.
• Pursue formulation and development partnerships to apply proprietary technology platforms.
• Monitor and manage ongoing patent infringement lawsuits related to Recorlev.
• Evaluate the timing and effects of adopting new accounting standards.

Key Dates

Recommendation

The strong revenue growth in Recorlev is a significant positive, indicating successful market penetration. However, the substantial loss on debt extinguishment, coupled with an increasing net loss and the ongoing legal challenges for Recorlev, introduces considerable risk. The company's liquidity appears adequate for the near term, but the potential need for future financing adds uncertainty. Therefore, a 'hold' recommendation is appropriate, pending further clarity on the resolution of legal matters and sustained profitability.

Keywords

biopharmaceutical, Recorlev, Gvoke, Keveyis, Cushing's syndrome, hypoglycemia, Primary Periodic Paralysis, XP-8121